Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Prime Medicine, Inc.’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
20
8 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
Prime Medicine, Inc. its own name
named as the applicant on its applications, in US
20 published
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 11, 2025 | 2025/0376674 | SPLIT PRIME EDITORS | Biotechnology | Prime Medicine, Inc. |
| Oct 16, 2025 | 2025/0319202 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY | Biotechnology | Prime Medicine, Inc. |
| Sep 25, 2025 | 2025/0297248 | METHODS AND COMPOSITIONS FOR INHIBITING MISMATCH REPAIR | Biotechnology | Prime Medicine, Inc. |
| Sep 25, 2025 | 2025/0297246 | MODIFIED PRIME EDITING GUIDE RNAS | Biotechnology | Prime Medicine, Inc. |
| Jul 31, 2025 | 2025/0243474 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE | Biotechnology | Prime Medicine, Inc. |
| Jun 5, 2025 | 2025/0179483 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1B | Biotechnology | Prime Medicine, Inc. |
| Mar 6, 2025 | 2025/0073352 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | Biotechnology | Prime Medicine, Inc. |
| Jan 9, 2025 | 2025/0011766 | Genome Editing Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosis | Biotechnology | Prime Medicine, Inc. |
| Dec 26, 2024 | 2024/0424138 | GENOME EDITING COMPOSITIONS AND METHOD FOR TREATMENT OF RETINITIS PIGMENTOSA | Biotechnology | Prime Medicine, Inc. |
| Nov 21, 2024 | 2024/0382620 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 3 | Biotechnology | Prime Medicine, Inc. |
What it applied for, 2024 to 2025: Biotechnology 19.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.